Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe

被引:43
作者
Hansson, L
Lloyd, A
Anderson, P
Kopp, Z
机构
[1] Fourth Hurdle Consulting Ltd, London WC1R 4QA, England
[2] Uppsala Univ, Dept Publ Hlth & Social Sci, Uppsala, Sweden
[3] Pfizer Inc, Outcomes Res, New York, NY 10017 USA
关键词
blood pressure; blood pressure targets; burden of illness; cost of illness; economics; hypertension;
D O I
10.1080/080370502753543945
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: To estimate the burden of failing, to achieve targets for blood pressure (BP) control in France, Germany, Italy, Sweden and the UK. Methods: A cost of illness model was constructed to estimate the impact of uncontrolled hypertension to each national healthcare system. Prevalence of uncontrolled hypertension was taken from published data. Relationships between achieved BP and the cardiovascular events of symptomatic acute myocardial infarction, congestive heart failure and stroke were estimated from the HOT study. Costs were taken from public sources. The acute medical costs of these events were estimated at current prevalence of uncontrolled hypertension and if BP were treated to target. Results: The model estimated that 29 million adults in the five countries (13% population) have BP levels above 160/95 mmHg, and an additional 46 million (21% population) have BP in the range 140/90-160/95 mmHg. The model estimated that healthcare system costs of 1.216 billion euros could be avoided if hypertension management did achieve BP targets. This does not consider the cost of interventions required to reduce the risk of cardiovascular disease. Conclusions: Failing to achieve BP targets contributes substantially to healthcare system costs and preventable events in the countries studies.
引用
收藏
页码:35 / 45
页数:11
相关论文
共 63 条
[11]  
CASIGLIA E, 1994, JPN HEART J, V35, P589
[12]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[13]   Blood pressure screening, management and control in England: results from the health survey for England 1994 [J].
Colhoun, HM ;
Dong, W ;
Poulter, NR .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :747-752
[14]   BLOOD-PRESSURE, ANTIHYPERTENSIVE DRUG-TREATMENT AND THE RISKS OF STROKE AND OF CORONARY HEART-DISEASE [J].
COLLINS, R ;
MACMAHON, S .
BRITISH MEDICAL BULLETIN, 1994, 50 (02) :272-298
[15]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838
[16]  
*CRED, OECD HLTH DAT 2000 C
[17]   MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION) [J].
DAHLOF, B ;
LINDHOLM, LH ;
HANSSON, L ;
SCHERSTEN, B ;
EKBOM, T ;
WESTER, PO .
LANCET, 1991, 338 (8778) :1281-1285
[18]  
Di Bari M, 1999, J HYPERTENS, V17, P1633
[19]  
EKPO EB, 1994, J HUM HYPERTENS, V8, P539
[20]   HEART-FAILURE - A GROWING PUBLIC-HEALTH PROBLEM [J].
ERIKSSON, H .
JOURNAL OF INTERNAL MEDICINE, 1995, 237 (02) :135-141